Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

FDA approval obtained for Prandin

Dec. 29, 1997

Otsuka's new antidiabetic agents

Dec. 29, 1997

Neurogen updates its NPY program for obesity

Dec. 24, 1997

Biorex and Abbott sign definitive agreement for bimoclomol

Dec. 23, 1997

Forbes files IND to begin phase II trials of Cardiorex in primary hypercholesterolemia

Dec. 23, 1997

GH secretagogues under development at Merck

Dec. 23, 1997

Lilly research leads to the discovery of new antiobesity compounds

Dec. 23, 1997

Isolation, structural elucidation and preliminary biological evaluation of new XOD inhibitor

Dec. 22, 1997

Flt3 ligand stimulates production of fully functional dendritic cells

Dec. 22, 1997

Hemolink enters phase II trials for second indication

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...